QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) | |||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Large accelerated filer | ☐ | ☒ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ||
Emerging growth company |
i | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Page | ||
1 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
April 4, 2026 | January 3, 2026 | ||
Assets | (unaudited) | (audited) | |
Current assets: | |||
Cash and cash equivalents | $ | $ | |
Accounts receivable, net of allowances of $ | |||
Inventories | |||
Prepaid expenses | |||
Other current assets | |||
Total current assets | |||
Non-current assets: | |||
Property and equipment, net | |||
Operating lease right-of-use assets | |||
Goodwill and intangible assets, net | |||
Deferred income taxes | |||
Other non-current assets | |||
Total assets | $ | $ | |
Liabilities and Shareholders’ Deficit | |||
Current liabilities: | |||
Borrowings under credit facility | $ | $ | |
Accounts payable | |||
Customer prepayments | |||
Accrued sales returns | |||
Compensation and benefits | |||
Taxes and withholding | |||
Operating lease liabilities | |||
Other current liabilities | |||
Total current liabilities | |||
Non-current liabilities: | |||
Operating lease liabilities | |||
Other non-current liabilities | |||
Total liabilities | |||
Shareholders’ deficit: | |||
Undesignated preferred stock; | |||
Common stock, $ and outstanding, respectively | |||
Additional paid-in capital | |||
Accumulated deficit | ( | ( | |
Total shareholders’ deficit | ( | ( | |
Total liabilities and shareholders’ deficit | $ | $ |
2 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | ||||
April 4, 2026 | March 29, 2025 | |||
Net sales | $ | $ | ||
Cost of sales | ||||
Gross profit | ||||
Operating expenses: | ||||
Sales and marketing | ||||
General and administrative | ||||
Research and development | ||||
Restructuring costs | ||||
Total operating expenses | ||||
Operating (loss) income | ( | |||
Interest expense, net | ||||
Loss before income taxes | ( | ( | ||
Income tax expense (benefit) | ( | |||
Net loss | $( | $( | ||
Basic and diluted net loss per share: | ||||
Net loss per share – basic and diluted | $( | $( | ||
Weighted-average shares – basic and diluted | ||||
3 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total | ||||||
Shares | Amount | ||||||||
Balance at January 3, 2026 | $ | $ | $( | $( | |||||
Net loss | — | — | — | ( | ( | ||||
Stock-based compensation | — | ||||||||
Repurchases of common stock | ( | ( | ( | — | ( | ||||
Balance at April 4, 2026 | $ | $ | $( | $( | |||||
Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total | ||||||
Shares | Amount | ||||||||
Balance at December 28, 2024 | ( | ( | |||||||
Net loss | — | — | — | ( | ( | ||||
Stock-based compensation | — | ||||||||
Repurchases of common stock | ( | — | ( | — | ( | ||||
Balance at March 29, 2025 | ( | ( | |||||||
4 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Cash flows from operating activities: | |||
Net loss | $( | $( | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | |||
Stock-based compensation | |||
Inventory obsolescence write off | |||
Loss on disposal and impairment of leased assets | |||
Deferred income taxes | ( | ||
Changes in operating assets and liabilities: | |||
Accounts receivable | |||
Inventories | ( | ||
Income taxes | |||
Prepaid expenses and other assets | ( | ||
Accounts payable | |||
Customer prepayments | ( | ||
Accrued compensation and benefits | ( | ||
Other taxes and withholding | ( | ( | |
Other accruals and liabilities | ( | ( | |
Net cash used in operating activities | ( | ( | |
Cash flows from investing activities: | |||
Purchases of property and equipment | ( | ( | |
Net cash used in investing activities | ( | ( | |
Cash flows from financing activities: | |||
Net increase in short-term borrowings | |||
Repurchases of common stock | ( | ( | |
Debt issuance costs | ( | ( | |
Net cash provided by financing activities | |||
Net decrease in cash and cash equivalents | ( | ( | |
Cash and cash equivalents, at beginning of period | |||
Cash and cash equivalents, at end of period | $ | $ | |
5 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
6 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
April 4, 2026 | January 3, 2026 | ||
Raw materials | $ | $ | |
Work in progress | |||
Finished goods | |||
$ | $ |
7 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
2026 (excluding the three months ended April 4, 2026 ) | $ | |
2027 | ||
2028 | ||
2029 | ||
2030 | ||
Total future amortization for definite-lived intangible assets | $ |
8 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
April 4, 2026 | January 3, 2026 | ||
Outstanding borrowings | $ | $ | |
Outstanding letters of credit | $ | $ | |
Additional borrowing capacity | $ | $ | |
Weighted-average interest rate |
9 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Operating lease costs(1) | $ | $ | |
Variable lease costs(2) | $( | $ | |
2026 (excluding the three months ended April 4, 2026) | $ |
2027 | |
2028 | |
2029 | |
2030 | |
2031 | |
Thereafter | |
Total operating lease payments(2) | |
Less: Interest | |
Present value of operating lease liabilities | $ |
April 4, 2026 | January 3, 2026 | |||
Weighted-average remaining lease term (in years) | ||||
Weighted-average discount rate |
Three Months Ended | ||||
(in thousands) | April 4, 2026 | March 29, 2025 | ||
Cash paid for amounts included in present value of operating lease liabilities(1) | $ | $ | ||
Right-of-use assets obtained in exchange for operating lease liabilities | $ | $ | ||
10 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
April 4, 2026 | January 3, 2026 | ||
Deferred contract assets included in: | |||
Other current assets | $ | $ | |
Other non-current assets | |||
$ | $ |
April 4, 2026 | January 3, 2026 | ||
Deferred contract liabilities included in: | |||
Other current liabilities | $ | $ | |
Other non-current liabilities | |||
$ | $ |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Retail stores | $ | $ | |
Online, phone, chat and other | |||
Total Company | $ | $ | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Balance at beginning of year | $ | $ | |
Additions that reduce net sales | |||
Deductions from reserves | ( | ( | |
Balance at end of period | $ | $ | |
11 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Stock awards(1) | $ | $ | |
Stock options | |||
Total stock-based compensation expense (1) | $ | $ | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Net loss | $( | $( | |
Reconciliation of weighted-average shares outstanding: | |||
Basic weighted-average shares outstanding | |||
Dilutive effect of stock-based awards | |||
Diluted weighted-average shares outstanding | |||
Net loss per share – basic and diluted | $( | $( | |
12 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Cash restructuring costs: | |||
Contract termination costs(1) | $ | $( | |
Severance and employee-related benefits | |||
Professional fees and other | |||
Total cash restructuring costs | |||
Non-cash restructuring costs: | |||
Asset impairments(2) | |||
Total restructuring costs | $ | $ | |
April 4, 2026 | January 3, 2026 | ||
Balance at the beginning of year | $ | $ | |
Expenses | |||
Cash payments | ( | ( | |
Balance at the end of the period | $ | $ |
Cumulative | ||
April 4, 2026 | ||
Cash restructuring costs: | ||
Contract termination costs(1) | $ | |
Severance and employee-related benefits | ||
Professional fees and other | ||
Total cash restructuring costs | ||
Non-cash restructuring costs: | ||
Asset impairments(2) | ||
Total restructuring costs | $ |
13 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | ||||
April 4, 2026 | March 29, 2025 | |||
Net Sales | $ | $ | ||
Less: | ||||
Cost of sales | ( | ( | ||
Marketing expenses | ( | ( | ||
Selling expenses | ( | ( | ||
General and administrative | ( | ( | ||
Research and development | ( | ( | ||
Restructuring costs | ( | ( | ||
Interest expense | ( | ( | ||
Income tax (expense) benefit | ( | |||
Net loss | $( | $( | ||
14 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Balance at beginning of period | $ | $ | |
Additions charged to costs and expenses for current-year sales | |||
Deductions from reserves | ( | ( | |
Changes in liability for pre-existing warranties during the current year, including expirations | ( | ||
Balance at end of period | $ | $ | |
15 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
16 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
17 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
18 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | |||||||
April 4, 2026 | March 29, 2025 | ||||||
Net sales | $319.0 | 100.0% | $393.3 | 100.0% | |||
Cost of sales | 134.4 | 42.1% | 152.7 | 38.8% | |||
Gross profit | 184.6 | 57.9% | 240.5 | 61.2% | |||
Operating expenses: | |||||||
Sales and marketing | 160.8 | 50.4% | 189.1 | 48.1% | |||
General and administrative | 33.6 | 10.5% | 38.6 | 9.8% | |||
Research and development | 5.3 | 1.7% | 10.9 | 2.8% | |||
Restructuring costs | 21.7 | 6.8% | 0.1 | 0.0% | |||
Total operating expenses | 221.5 | 69.4% | 238.7 | 60.7% | |||
Operating (loss) income | (36.9) | (11.6%) | 1.9 | 0.5% | |||
Interest expense, net | 13.1 | 4.1% | 11.1 | 2.8% | |||
Loss before income taxes | (50.0) | (15.7%) | (9.2) | (2.3%) | |||
Income tax expense (benefit) | 0.3 | 0.1% | (0.6) | (0.1%) | |||
Net loss | $(50.3) | (15.8%) | $(8.6) | (2.2%) | |||
Net loss per share: | |||||||
Basic and diluted | $(2.19) | $(0.38) | |||||
Weighted-average number of common shares: | |||||||
Basic and diluted | 23.0 | 22.7 | |||||
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Retail stores | 87.0% | 87.6% | |
Online, phone, chat and other | 13.0% | 12.4% | |
Total Company | 100.0% | 100.0% | |
19 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Sales change rates: | |||
Retail comparable-store sales (1) | (17%) | (15%) | |
Online, phone and chat | (15%) | (12%) | |
Total Retail comparable sales change (1) | (16%) | (15%) | |
Net opened/closed stores and other | (3%) | (1%) | |
Total Company | (19%) | (16%) | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Average sales per store (1) (in thousands) | $2,170 | $2,495 | |
Average sales per square foot (1) | $700 | $807 | |
Stores > $2 million in net sales (2) | 31% | 51% | |
Stores > $3 million in net sales (2) | 6% | 15% | |
Average revenue per mattress unit – Total Retail (3) | $6,021 | $5,992 | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Beginning of period | 600 | 640 | |
Opened | — | 2 | |
Closed | (23) | (5) | |
End of period | 577 | 637 | |
20 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
21 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
22 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
23 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Total cash (used in) provided by: | |||
Operating activities | $(7.8) | $(2.6) | |
Investing activities | (5.4) | (4.6) | |
Financing activities | 13.0 | 7.0 | |
Net decrease in cash and cash equivalents | $(0.2) | $(0.3) | |
24 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Trailing-Twelve Months Ended | ||||||
April 4, 2026 | March 29, 2025 | April 4, 2026 | March 29, 2025 | ||||
Net loss | $(50,297) | $(8,646) | $(173,609) | $(21,498) | |||
Income tax expense (benefit) | 338 | (585) | 36,907 | (6,472) | |||
Interest expense | 13,103 | 11,081 | 51,404 | 47,150 | |||
Depreciation and amortization | 11,126 | 14,406 | 49,889 | 62,240 | |||
Stock-based compensation | 2,827 | 3,951 | 5,158 | 11,278 | |||
Restructuring costs(1) | 21,736 | 60 | 72,373 | 7,526 | |||
Other non-recurring items(2) | 6,917 | 1,774 | 19,841 | 2,772 | |||
Asset impairments | — | — | — | 1,220 | |||
Adjusted EBITDA | $5,750 | $22,041 | $61,963 | $104,216 | |||
25 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Three Months Ended | Trailing-Twelve Months Ended | ||||||
April 4, 2026 | March 29, 2025 | April 4, 2026 | March 29, 2025 | ||||
Net cash used in operating activities | $(7,751) | $(2,626) | $(8,408) | $(9,228) | |||
Subtract: Purchases of property and equipment | 5,441 | 4,599 | 15,249 | 18,796 | |||
Free cash flow | $(13,192) | $(7,225) | $(23,657) | $(28,024) | |||
Trailing-Twelve Months Ended | |||
April 4, 2026 | March 29, 2025 | ||
Adjusted net operating profit after taxes (Adjusted NOPAT) | |||
Operating income | $(85,299) | $19,180 | |
Add: Operating lease expense (1) | 23,832 | 26,098 | |
Less: Income taxes (2) | 7,902 | (10,022) | |
Adjusted NOPAT | $(53,565) | $35,256 | |
Average adjusted invested capital | |||
Total deficit | $(626,317) | $(456,844) | |
Add: Long-term debt (3) | 605,720 | 557,921 | |
Add: Operating lease obligations (4) | 348,037 | 376,909 | |
Total adjusted invested capital at end of period | $327,440 | $477,986 | |
Average adjusted invested capital (5) | $408,437 | $487,361 | |
Adjusted return on invested capital (Adjusted ROIC) (6) | (13.1%) | 7.2% | |
26 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
27 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
28 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Period | Total Number of Shares Purchased(1)(2) | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1) | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(3) | ||||
January 4, 2026 through January 31, 2026 | 2,219 | $10.49 | — | $348,071,000 | ||||
February 1, 2026 through February 28, 2026 | 320 | $9.42 | — | $348,071,000 | ||||
March 1, 2026 through April 4, 2026 | 100,752 | $3.44 | — | $348,071,000 | ||||
Total | 103,291 | $3.61 | — | $348,071,000 |
29 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
Exhibit Number | Description | |
10.1 | ||
10.2* | ||
31.1* | ||
31.2* | ||
32.1* | ||
32.2* | ||
101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
30 | 1Q 2026 FORM 10-Q | SLEEP NUMBER CORPORATION | |
SLEEP NUMBER CORPORATION | |||
(Registrant) | |||
Dated: | May 12, 2026 | By: | /s/ Linda Findley |
Linda Findley | |||
President and Chief Executive Officer | |||
(principal executive officer) | |||
By: | /s/ Amy K. O’Keefe | ||
Amy K. O’Keefe | |||
Chief Financial Officer | |||
(principal financial officer) | |||
By: | /s/ Kelly F. Baker | ||
Kelly F. Baker | |||
Principal Accounting Officer | |||
(principal accounting officer) | |||